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Background: In recent years, there has been an increased interest in using recombinant adeno-associated viruses
(AAV) to make localized genetic manipulations within the rodent brain. Differing serotypes of AAV possess divergent
capsid protein sequences and these variations greatly influence each serotype’s ability to transduce particular cell
types and brain regions. We therefore aimed to determine the AAV serotype that is optimal for targeting neurons
within the Basal and Lateral Amygdala (BLA) since the transduction efficiency of AAV has not been previously examined
within the BLA. This region is desirable to genetically manipulate due to its role in emotion, learning & memory, and
numerous psychiatric disorders. We accomplished this by screening 9 different AAV serotypes (AAV2/1, AAV2/2,
AAV2/5, AAV2/7, AAV2/8, AAV2/9, AAV2/rh10, AAV2/DJ and AAV2/DJ8) designed to express red fluorescent protein
(RFP) under the regulation of an alpha Ca2+/calmodulin-dependent protein kinase II promoter (αCaMKII).
Results: We determined that these serotypes produce differing amounts of virus under standard laboratory
production. Notably AAV2/2 consistently produced the lowest titers compared to the other serotypes examined.
These nine serotypes were bilaterally infused into the rat BLA at the highest titers achieved for each serotype and
at a normalized titer of 7.8E + 11 GC/ml. Twenty one days following viral infusion the degree of transduction was
quantitated throughout the amygdala. These viruses exhibited differential transduction of neurons within the BLA.
AAV2/7 exhibited a trend toward having the highest efficiency of transduction and AAV2/5 exhibited significantly lower
transduction efficiency as compared to the serotypes examined. AAV2/5′s decreased ability to transduce BLA neurons
correlates with its significantly different capsid protein sequences as compared to the other serotypes examined.
Conclusions: For laboratories producing their own recombinant adeno-associated viruses, the use of AAV2/2 is likely
less desirable since AAV2/2 produces significantly lower titers than many other serotypes of AAV. Numerous AAV
serotypes appear to efficiently transduce BLA neurons, with the exception of AAV2/5. Taking into consideration the
ability of certain serotypes to achieve high titers and transduce BLA neurons well, in our hands AAV2/DJ8 and AAV2/9
appear to be ideal serotypes to use when targeting neurons within the BLA.Background
Numerous genetic manipulation strategies have been de-
veloped to study complex interactions between gene ex-
pression and behavior. These strategies are essential to
study the role and function of genes in complex systems
such as the brain [1-5]. Gene manipulation strategies are
designed to alter the genetic makeup in certain cells or* Correspondence: Jonathan.Ploski@UTDallas.edu
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distribution, and reproduction in any mediumtissue types either by over- expressing or knocking down
specific genes. Some of the common methods currently
being used for this purpose are traditional transgenic
animal technology [6] and the relatively newer method
utilizing recombinant viral vectors [7].
Within neuroscience, recombinant viral vector tech-
nology allows the targeting of localized populations of
neurons or other cell types within specific parts of the
nervous system. Recombinant viruses engineered to har-
bor transgenes of interest can be infused directly into
desired brain regions where the virus can then transducentral Ltd. This is an Open Access article distributed under the terms of the
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transgene cargo thereby genetically modifying the tar-
geted cells [8]. One of the greatest benefits of this tech-
nology is that it allows the genetic manipulation to be
introduced at virtually any point in the organism’s life
span quickly and easily. This is especially valuable in be-
havioral neuroscience research since the virus/transgene
can be introduced before or after behavior experiments;
thereby allowing it to be determined how the precise
genetic manipulation specifically modifies specific as-
pects of the organism’s behavior [3,9-11].
The Adeno-Associated Virus (AAV) is an ideal virus
to use for in vivo purposes since it is well tolerated
in vivo and can be easily produced within the laboratory
at titers necessary for this use. AAV does not cause dis-
ease and does not induce a significant inflammatory or
immune response in vivo [12-20]. This class of viruses
also exhibits stable and long lasting transgene expression
and a wide range of infectivity [17,21]. Numerous AAV
serotypes have been isolated from adenoviral stocks
[22,23], from humans [24-26] and from primate tissues
[24-26]; some AAV serotypes have also been engineered
by directed evolution [27-29]. These AAV serotypes pos-
sess three different capsid proteins: Virion Proteins 1, 2, 3
(VP1, VP2 and VP3). Of these, VP1 is the largest capsid
protein of the three, while VP2 and VP3 are produced
through differences in splicing and translation initi-
ation. Variations in the capsid protein amino acid
composition among the AAV serotypes contribute to
each serotype’s ability to transduce particular cell
types [30-33].
Among the different AAV serotypes, AAV2 has been
the most commonly used in neuroscience research, how-
ever; recent studies have determined that the transduc-
tion efficiency of this serotype is sub‐optimal for some
brain cells and tissues [33-35]. These studies are incred-
ibly important because they underscore that the choice
of virus/serotype should be made wisely since all AAV
serotypes may not necessarily transduce the target cell/
tissue intended. Unlike traditional transgenic animal tech-
nology that typically genetically manipulates every cell or
specific cell type within the whole organism, recombinant
viral vector technology must be optimized to achieve
transduction of as many cells as possible within the de-
sired region. Optimal transduction is dependent on
the viral titers that can be achieved and the efficiency
of a particular virus for transducing a particular cell
type.
Here we examined the ability of 9 different AAV sero-
types (seven naturally occurring; AAV1, AAV2, AAV5,
AAV7, AAV8, AAV9, AAVrh10 and two engineered
though directed evolution; AAVDJ and AAVDJ8) in their
ability to transduce neurons within the Basal and LateralAmygdala (BLA). Targeting neurons within the BLA is of
great interest for many in the neuroscience community
due to the role of the BLA in emotional learning and
memory [36-38], and psychiatric disorders [39,40]; import-
antly there are no previous reports on how effective
these serotypes are at transducing neurons within the
BLA.Results
Pseudotyped viruses are essentially identical, except for
their capsid proteins
To examine how AAV serotypes may differ in their
intrinsic ability to transduce neurons within the Basal
and Lateral Amygdala (BLA) an AAV2 genome plasmid
harboring a red fluorescent protein gene, under the con-
trol of the neuron specific mouse αCaMKII promoter
(AAV-RFP) [41,42], was pseudotyped into nine different
AAV serotypes (AAV2/1, AAV2/2, AAV2/5, AAAV2/7,
AAV2/8, AAV2/9, AAV2/rh10, AAV2/DJ and AAV2/
DJ8). These pseudotyped viruses are essentially identical,
except for their capsid proteins, VP1, VP2 and VP3. Se-
quence analysis of the largest capsid protein for each of
these serotypes (i.e. VP1) highlights the degree to which
these serotypes differ (Figure 1). Notably AAV5 differs
the most relative to the other serotypes, exhibiting ~40%
sequence divergence from these serotypes. The genetic-
ally engineered serotypes AAVDJ, and AAVDJ8 are very
similar to each other; their closest relative is AAV2.
Most of these serotypes differ by ~10-20%.Serotypes of AAV produce differing viral yields
Following viral purification, the viruses were titered using
a qRT-PCR based method to determine the number of
viral genome copies per ml from DNase resistant viral
particles. This method of titering provides the most ac-
curate method to quantitatively compare viral yields
from differing serotypes because it does not depend on
viral transduction efficiency, which may naturally differ
among serotypes. Following titering of these nine differ-
ent viruses, it became apparent that there were large dif-
ferences in the titers achieved for some of these
serotypes (Figure 2B and C). AAV2/2 produced the low-
est titer and AAV2/5 produced the highest titer. To en-
sure that the AAV2/2 titers were not due to an anomaly
with the AAV2 serotype plasmid, AAV2/2 virus was
produced again using a different AAV2 serotype plasmid
obtained from another source (see methods) and it is re-
ferred to here as AAV2*. Both AAV2/2 and AAV2/2*
produced lower titers as compared to the other 8 sero-
types produced. Because some variability in viral titer
Figure 1 Relative differences in amino acid composition among AAV serotype VP 1 proteins examined in this study. (A). Phenogram
comparing graphically the relative differences among AAV serotype VP1 proteins. (B). Percent similarity and divergence table comparing the
relative differences among AAV serotype VP1 proteins.
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we next examined the ability of these serotypes to pro-
duce packaged virus using a crude viral lysate from a
small scale experiment performed in triplicate (Fig-
ure 2D). This small scale viral production experiment
yielded similar findings to the large scale experiment:
AAV2/2 produced significantly lower viral yields com-
pared to the other serotypes. AAV2/2 is not however
the only virus that is prone to producing lower yields
upon large scale viral production. For example, when
the AAV2 genome plasmid harboring an RFP gene
(AAV-RFP) was pseudotyped as AAV2/1, it produced ti-
ters that were on the lower end of viral yields as com-
pared to the other serotypes that were purified
(Figure 2B and C). When another AAV2 genome plas-
mid referred to here as AAV-misc was used to gener-
ate fully purified viruses that were pseudotyped as
AAV2/1 and AAV2/DJ8, AAV2/DJ8 consistently pro-
duced viral titers in the range of 3E + 13 GC/ml,
while AAV1 produced approximately 10 fold lower
titers (Figure 2E).
AAV serotypes differentially transduce neurons within the
rat BLA
We next examined whether these 9 AAV serotypes differ
in their ability to transduce neurons within the BLA
(Figure 3). Because it was unknown what viral titer
would prove optimal for infusion into the BLA, we first
bilaterally infused each serotype at the highest titer
achieved for each serotype (i.e. each serotype was in-
fused at a different titer). Twenty one days following
viral infusion, the rats were sacrificed, perfused and the
amount of viral transduction was examined for eachserotype throughout the entire amygdala (Bregma -1.80
to -4.16) (Figure 4). Since multiple viral particles are
capable of transducing individual cells within the target
region, and therefore able to deliver a differential num-
ber of copies of the RFP transgene to the target cells, it
is necessary to measure the intensity of RFP fluorescence
(optical density, OD) and the spread of viral transduc-
tion (area of cells containing RFP expression) to ad-
equately measure efficiency of viral transduction among
differing serotypes. Additionally, because targeted viral in-
fusions within the rodent brain, even under the best cir-
cumstances will not entirely localize viral transduction to
the intended target region, we specifically measured the
intensity and spread of RFP fluorescence for the entire
transduced region in each examined amygdala-containing
coronal slice (see Methods) and we refer to these mea-
surements as “Total”. We also measured the intensity
and spread of RFP fluorescence within the BLA to
determine “BLA only” measurements. The Total and
BLA only measurements are graphed side-by-side
(Figure 5).
In this experiment it became clear that high viral titers
did not guarantee high viral transduction. For example,
AAV2/5 had the highest titer of any serotype produced,
but transduced BLA neurons modestly with respect to
many of the other serotypes examined. At the titers
achieved for AAV2/2 and AAV2/2*, no viral transduction
was observed within the BLA. Serotypes AAV2/DJ8
and AAV2/9 possessed the highest level of transduc-
tion of BLA neurons in this experiment. Notably
there was a high level of viral transduction that span-
ned the entire anterior-posterior axis of the BLA
(Figure 5D), without any noticeable damage to the
tissue.
Figure 2 AAV serotypes produce differing titers of virus following laboratory production. (A). Schematic diagram of AAV2 genome
plasmids used in this study. AAV-RFP contains a red fluorescent protein gene (dsRed-Express) controlled by a mouse αCaMKII promoter that has
been previously described [41]. AAV-misc has been previously described [43]. Both AAV2 genome plasmids contain genomes that span ~3300
bps (left inverted terminal repeat (ITR) to right ITR). (B). Viral titers obtained following iodixanol purification. (C). Viral titers obtained in (B).
displayed as a table. (D). Viral titers obtained from crude viral lysates following small scale viral production. AAV2/2 produces significantly less
packaged virus compared to the other serotypes examined. ANOVA p < .0001; Fisher’s Post-hoc test p < .05 for AAV2/2 and AAV2/2* compared
to all other groups. n = 3. Error bars equal standard error of the mean (SEM). (E) AAV2/1 viral titers are ~ 10 fold less compared to AAV2/DJ8 viral
titers following full scale production and iodixanol gradient purification. Viral titers for AAV-RFP viruses pseudotyped as AAV2/1 and AAV2/DJ8
(n = 1) are displayed next to viral titers for AAV-misc viruses pseudotyped at AAV2/1 (n = 2) and AAV2/DJ8 (n = 3). Error bars = SEM. Graphs
displayed in B. D. and E. have logarithmic scales.
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at differing titers, however; to examine AAV serotype
transduction efficiency of BLA neurons quantitatively
it was necessary to infuse the viruses at the same viral
titer. In the next experiment, these serotypes wereFigure 3 Graphical depiction of the rat LA and B nuclei, (BLA) targete
amygdala as previously described [44].bilaterally infused into the rat BLA at a normalized titer
of 7.8E + 11 GC/ml and 21 days following viral infusion
the rats were sacrificed and the degree of transduction
was quantitated throughout the amygdala as described
above (Figures 6 and 7). In addition the number ofd within this study. Anatomy across the anterior-posterior axis of the
Figure 4 Representative coronal images containing the amygdala (~ Bregma -3.3) depicting AAV-RFP viral transduction for selected
AAV serotypes (RFP fluorescence) and associated bright field images. In this experiment, AAV-RFP virus was pseudotyped as AAV2/1, 2/2,
2/5, 2/7, 2/8, 2/9, 2/rh10, 2/DJ, or 2/DJ8 and infused into the BLA at the highest titer achieved for each respective serotype (see Figure 2C). Images
of coronal brain sections containing the amygdala are arranged for each serotype as follows: bright field image (scale bar = 500 μm), RFP image,
and magnified view of a portion of the BLA region of the adjacent RFP image to allow visualization of the cellular detail (scale bar = 100 μm).
LA = lateral nucleus of the amygdala, B = basal nucleus of the amygdala. For publication purposes, RFP images for AAV1, 5, 7, and 8 were slightly
enhanced to increase clarity. AAV2/2 and AAV2/2* are the same serotype (see Methods) and neither of these viruses transduced any cells within
the BLA at the respective titers achieved.
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transduction (total) and for transduction confined to the
BLA (BLA only) (Figure 7). It was necessary to use a
longer exposure time to capture the viral transduction
images for this experiment since generally fewer viral
particles were infused into the BLA as compared to the
previous experiment. These data depicted in Figures 6
and 7, therefore, cannot be directly compared to data
depicted in Figures 4 and 5 (see Methods).
These viruses exhibited differential transduction of
neurons within the BLA. It is of interest that AAV2/5
(total and BLA only) exhibited the lowest viral transduc-
tion efficiency (mean viral transduction and number of
transduced cells) as compared to the other 7 serotypes ex-
amined (Kruskal-Wallis test, Dunn-Bonferroni post hoc;
p < .05). These findings were unambiguous since AAV2/5consistently did not transduce cells within or around the
BLA across replicates within this experiment. AAV sero-
types 2/1, 2/7, 2/8, 2/9, 2/rh10, 2/DJ, and 2/DJ8 exhibited
relatively comparable levels of transduction efficiency,
with AAV2/7 exhibiting a trend for the highest level of
transduction. Tables containing the p-values from statis-
tical comparisons among the serotypes for mean viral
transduction (total and BLA only), mean viral spread (total
and BLA only) and mean number of transduced cells
(total and BLA only) are provided in (Additional file 1:
Table S1). AAV2/2 and AAV2/2* were not included in this
experiment because the titers achieved for these viruses
did not exhibit transduction of BLA neurons and these ti-
ters were below 7.8E + 11 GC/ml.
The viruses utilized within this study were designed to
express RFP from a neuron specific mouse αCaMKII
Figure 5 Quantitation of viral transduction depicted in Figure 4. In this experiment, AAV-RFP virus was pseudotyped as AAV2/1, 2/2, 2/5, 2/7,
2/8, 2/9, 2/rh10, 2/DJ, or 2/DJ8 and infused into the BLA at the highest titer achieved for each respective serotype (see Figure 2C). (A). Viral
transduction (OD * area (μm2)) was quantified for each viral infusion and these data were averaged across infusions and reported as mean viral
transduction. These measurements included measuring the entire amount of transduction (Total) and the viral transduction that was confined to
the BLA (BLA only). These data are displayed side-by-side for each serotype. (B). Viral OD was quantified for each viral infusion and these data
were averaged across infusions and reported as mean viral OD. These measurements included measuring the OD for the entire amount of
transduction (Total) and the OD for the viral transduction that was confined to the BLA (BLA only). These data are displayed side-by-side for each
serotype. (C). Viral spread (area (μm2)), was quantified for each viral infusion and these data were averaged across infusions and reported as mean
viral spread. These measurements included measuring the viral spread for the entire viral transduction (Total) and the viral spread for the viral
transduction that was confined to the BLA (BLA only). These data are displayed side-by-side for each serotype. (D). For analysis of viral transduction
across the anterior-posterior axis of the BLA, the amygdala was subdivided into 5 regions with respect to Bregma: -2.3 (-1.8 - -2.7); -2.8 (-2.7 - -3.1); -3.3
(-3.1 - -3.4); -3.6 (-3.4 - -3.7); 3.8 (-3.7 - -4.0) (see Figure 3) and the total BLA only transduction was quantified within each subregion. Graphs displayed in
A. C. and D. have logarithmic scales. Error bars represent the standard error of the mean.
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viruses transduce, only αCaMKII positive neurons would
likely express the RFP. To examine if this prediction held
true, we performed immunohistochemistry on BLA con-
taining coronal slices that were transduced with serotypes
2/1, 2/7, 2/8, 2/9, 2/rh10, 2/DJ, and 2/DJ8 since these sero-
types exhibited BLA transduction in the previous experi-
ment. The proportion of RFP expressing cells that were
also NeuN positive was examined and it was determined
that ~98% of RFP expressing cells were also NeuN positive
indicating that the RFP signal predominantly came from
neurons (Figures 8 and 9). These data are consistent with
the fact, that for the AAV serotypes examined thus far
within the rodent central nervous system, all of them pre-
dominantly transduce neurons [34,35,45-49]. Next the
proportion of RFP expressing cells that was also immuno
positive for αCaMKII protein was examined. It was deter-
mined that ~85% of RFP expressing cells were also αCaM-
KII positive (Figures 10 and 11).Discussion
The impetus for this study was based upon the observa-
tion that for AAV-mediated gene delivery to the BLA to
be truly effective, a large number of pertinent cells would
need to be transduced and this would require using an
AAV serotype that efficiently transduces the cell types of
interest within this region, at titers that can be realistically
obtained. Numerous studies have previously reported that
the degree of viral spread and transduction within particu-
lar brain regions and cells can vary depending on AAV
serotype [33,34,46,50]. For example, one study discovered
that AAV2/8 displayed greater transduction and spread
compared to AAV2/2 and AAV2/1 in numerous regions
within the mouse brain [46]. Another study found that
AAV2/2 did not transduce the dentate gyrus or CA1 ef-
fectively, which was in contrast to AAV2/1. Instead,
AAV2/2 infected the hilar region of the dentate gyrus [34].
These studies underscore the importance of determining
which AAV serotype most effectively transduces the cell
Figure 6 Representative coronal images containing the amygdala (~ Bregma -3.3) depicting AAV-RFP viral transduction for selected
AAV serotypes (RFP fluorescence) and associated bright field images. In this experiment, AAV-RFP virus was pseudotyped as AAV2/1, 2/5,
2/7, 2/8, 2/9, 2/rh10, 2/DJ, or 2/DJ8 and infused into the BLA at the titer of 7.8E + 11 GC/ml. Images of coronal brain sections containing the
amygdala are arranged for each serotype as follows: bright field image (scale bar = 500 μm), RFP image, and magnified view of a portion of the
BLA region of the adjacent RFP image to allow visualization of the cellular detail (scale bar = 100 μm). LA = lateral nucleus of the amygdala,
B = basal nucleus of the amygdala. No transduction was observed for AAV5 in this experiment.
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may not transduce all cell types or brain regions well.
However these previous studies only examined a few sero-
types and none of these previous studies compared the
abilities of differing AAV serotypes to transduce BLA neu-
rons. Because of this it was necessary to screen AAV sero-
types in their ability to transduce neurons of the BLA. We
specifically sought to determine which serotypes are opti-
mal for transducing αCaMKII positive neurons within the
BLA since these neurons are critical for synaptic plasticity
relevant for amygdala dependent learning and memory
[36,38,51]. To accomplish this, we utilized an AAV2 gen-
ome plasmid that was designed to express RFP under the
control of an αCaMKII promoter, to direct the expression
of RFP predominantly in glutamatergic excitatory neurons
[41,42]. Our approach was collectively unique among
studies comparing differences among AAV serotypes in
transduction ability of the rodent brain in multiple ways.
First, we examined 9 different serotypes, the most of any
other study. Second, we are the first to report transduction
efficiency of AAV2/DJ and AAV2/DJ8 within the rodent
brain, and third, we examined neuron transduction utiliz-
ing an expression system that was controlled by anαCaMKII promoter, whereas all previous studies compar-
ing serotypes within the rodent brain utilized expression
systems that were controlled by general promoters (i.e.
cytomegalovirus (CMV) and Chicken β-actin (CBA)) that
drive expression in all cell types or pan-neuronal pro-
moters (i.e. Synapsin) that drive expression in all neuronal
types.
Our study revealed that of the 9 serotypes we exam-
ined, AAV2/2 consistently produced the lowest yield of
virus when produced under standard laboratory condi-
tions and it was incapable of transducing neurons within
the BLA at the titer achieved (1.7E + 10 GC/ml). In
contrast AAV2/9 and AAV2/DJ8 produced much higher
titers (2.2E + 13 GC/ml and 5.2E + 13 GC/ml respect-
ively), and possessed the greatest overall transduction of
BLA neurons at these titers among the serotypes tested.
Given its cited use, it is of great interest that AAV2/5
consistently produced the highest titer of any serotype
examined, but it possessed a modest ability to transduce
neurons within the BLA therefore making it a less
favorable choice for targeting neurons within the BLA.
Interestingly AAV2/5 exhibited not only the lowest
transduction efficiency of BLA neurons, but it is also the
Figure 7 Quantitation of viral transduction depicted in Figure 6. In this experiment, AAV-RFP virus was pseudotyped as AAV2/1, 2/5, 2/7, 2/8,
2/9, 2/rh10, 2/DJ, or 2/DJ8 and infused into the BLA at the titer of 7.8E + 11 GC/ml. (A). Viral transduction (OD * area (μm2)) was quantified and
depicted using methods described in Figure 5. (B). Viral OD was quantified and depicted using methods described in Figure 5. (C). Viral spread
(area (μm2)), was quantified and depicted using methods described in Figure 5. (D). The number of transduced cells was quantified for each viral
infusion and these data were averaged across infusions and reported as mean number of transduced cells. These measurements included measuring the
number of transduced cells for the entire viral transduction (Total) and the number of transduced cells for the viral transduction that were confined to
the BLA (BLA only). (E). For analysis of viral transduction across the anterior-posterior axis of the BLA, the amygdala was subdivided into 5 regions with
respect to Bregma: -2.3 (-1.8 - -2.7); -2.8 (-2.7 - -3.1); -3.3 (-3.1 - -3.4); -3.6 (-3.4 - -3.7); 3.8 (-3.7 - -4.0) (see Figure 3) and the total BLA only transduction was
quantified within each subregion. Graphs displayed in A. C. D. and E. have logarithmic scales. Error bars represent the standard error of the mean.
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as compared to the other serotypes examined. The AAV5
VP1 capsid sequence is ~40% different as compared to the
other 8 AAV serotypes, suggesting that AAV5′s significant
VP1 sequence divergence is associated with reduced BLA
neuronal transduction. AAV serotypes 2/1, 2/7, 2/8, 2/9,
2/rh10, 2/DJ, and 2/DJ8 exhibited comparable levels of
transduction efficiency, with AAV2/7 exhibiting a trend
for the highest level of transduction.
Using a small scale crude viral preparation it was
revealed that AAV serotypes differ in their intrinsicability to produce packaged virus; specifically that
AAV2/2 produced significantly less virus as compared
to the other serotypes examined. It is important to
note that the differences in viral yield among the
other serotypes to each other were relatively minor in
this experiment. An important advantage of using the
small scale crude viral preparation is that the viral
yield is not dependent on the purification method
(i.e. cesium chloride ultracentrifugation, iodixonal gra-
dient or affinity purification) and therefore differences
in the viral yield can be attributed to the virus itself.
Figure 8 Representative coronal images containing the BLA
(~ Bregma -3.3) depicting AAV-RFP viral transduction for selected
AAV serotypes (RFP fluorescence) and NeuN immunohistochemistry
(FITC fluorescence). In this experiment, AAV-RFP virus was pseudo-
typed as AAV2/1, 2/5, 2/7, 2/8, 2/9, 2/rh10, 2/DJ, or 2/DJ8 and infused
into the BLA at the titer of 7.8E + 11 GC/ml. Images of coronal brain
sections containing the BLA are arranged for each serotype as follows:
AAV-RFP image (scale bar = 100 μm), NeuN-FITC image and an image
of these two previous images merged. Arrows point to a subset of
NeuN positive cells that are also AAV-RFP positive.
Figure 9 Quantitation of data presented in Figure 8 to
determine the percent of AAV-RFP positive cells that are also
NeuN positive. Error bars represent the standard error of the mean.
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yields of the fully purified AAV-RFP virus among some of
the serotypes. Moreover, when AAV-misc was pseudo-
typed as AAV2/1 and AAV2/DJ8, the AAV2/1 titers ob-
tained were consistently ~10fold lower as compared to
AAV2/DJ8. These differences might not be due to varia-
tions in the production of each serotype, but may be due
to differences in how efficiently differing serotypes are
purified using the iodixonal gradient method.Conclusion
In conclusion this study determined that AAV serotypes
differ in their ability to produce virus and differ in their
ability to transduce neurons within the BLA. Based on
the ability of AAV2/DJ8 to produce high titers and trans-
duce neurons within the BLA exceptionally well at these
titers, our lab has begun to routinely utilize AAV2/DJ8 in
our ongoing experiments designed to target the BLA.
Methods
Subjects
Adult male Sprague Dawley rats (Charles River Labora-
tories) weighing 300-400 g were housed individually and
maintained on a 12 hr light / dark cycle. Food and water
were provided ad libitum throughout the experiment.
Animal use procedures were in accordance with the
National Institutes of Health Guide for the Care and Use
of laboratory animals and were approved by the Univer-
sity of Texas at Dallas Animal Care and Use Committee.
Large scale AAV production/purification
An AAV2 genome plasmid harboring an RFP gene con-
trolled by a mouse αCaMKII promoter (AAV-RFP) was
packaged into functional viruses that were pseudotyped
with different AAV capsid proteins to produce AAV se-
rotypes 2/1, 2/2, 2/5, 2/7, 2/8, 2/9, 2/rh10, 2/DJ and
2/DJ8. Pseudotyped viruses were produced using a
triple-transfection, helper-free method, and the resultant
viruses were purified on an iodixanol step gradient, as
previously described [43,52]. For producing each virus,
AAV-293 cells (Agilent Technologies) were seeded in
5×15 cm plates 24 hours before transfection so that at
the time of transfection the cells would be 80-85%
confluent. At the time of transfection 135 μg of pRC
(serotype plasmid), 135 μg of pHelper and 135 μg of
AAV2 genome plasmid harboring a red fluorescent
Figure 10 Representative coronal images containing the BLA
(~ Bregma -3.3) depicting AAV-RFP viral transduction for selected
AAV serotypes (RFP fluorescence) and αCaMKII immunohistochemistry
(FITC fluorescence). In this experiment, AAV-RFP virus was pseudotyped
as AAV2/1, 2/5, 2/7, 2/8, 2/9, 2/rh10, 2/DJ, or 2/DJ8 and infused into the
BLA at the titer of 7.8E + 11 GC/ml. Images of coronal brain sections
containing the BLA are arranged for each serotype as follows: AAV-RFP
image (scale bar = 100 μm), αCaMKII-FITC image and an image of
these two previous images merged. Arrows point to a subset of
αCaMKII positive cells that are also AAV-RFP positive.
Figure 11 Quantitation of data presented in Figure 10 to
determine the percent of AAV-RFP positive cells that are also
αCaMKII positive. Error bars represent the standard error of the mean.
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αCaMKII promoter (Addgene plasmid 22908) [41] were
used per each calcium phosphate mediated transfection.
The culture media was replaced 6 hours post-transfection
with pre-warmed standard growth media. At Seventy-two
hours post-transfection the cells were harvested by centri-
fugation (1500 g for 15 min), the supernatant was dis-
carded and the cells were re-suspended in 8 ml of freezing
buffer (0.15 M NaCl, 50 mM Tris, pH 8.0) and stored at
-80°C until purification. For virus purification, cells werelysed by two freeze/thaw cycles in dry ice-ethanol and
42°C water baths. Five hundred units of benzonase
(Novagen) was added to the lysate and incubated for 30
minutes at 37°C. The lysate was clarified by centrifugation
at 3700 g for 20 min and the supernatant was applied to
an iodixanol gradient column (15%, 25%, 40% and 57%
iodixanol). The columns were centrifuged at 50,000 rpm
for 3 hr 20 min at 10°C in a Type 70 Ti rotor (Beckman
Coulter). After centrifugation the 40% iodixanol layer was
extracted and transferred to a conical tube and diluted
with 25 ml of PBS-MK (1×PBS without calcium or magne-
sium, 1 mM MgCl2, 2.5 mM KCl) and concentrated using
Amicon Ultra-15 Centrifugal Filter Units (Millipore) to ~ 1
ml. This viral concentrate was diluted again with 10 ml of
PBS-MK and concentrated to a final volume of 100 μl and
stored at 4°C until use. All plasmids used were purified
using Qiagen Endofree plasmid purification kits following
the manufacturer’s instructions. AAV packaging plasmids
(pRC) for different serotypes were obtained from: AAV1,
AAV5 (Nicholas Muzyczka, University of Florida), AAV-2
(Agilent Technologies), AAV2*, AAVDJ and AAVDJ8
(Cell BioLabs, Inc), AAV7, AAV8, AAV9, AAVrh10 (Penn
Vector Core, University of Pennsylvania). AAV2 and
AAV2* are the same serotype but the AAV2 pack-
aging plasmid was obtained from a different source
(above). AAV Helper plasmid (pHelper) was obtained
from (Agilent Technologies). Since calcium phosphate
transfections are sensitive to the pH of the 2×HBS solu-
tion, we prepared 2×HBS at different pH (pH 7.04, 7.06,
7.08, 7.10 and 7.12) and tested them in small scale transfec-
tions in a 6 well plate with a GFP reporter plasmid to
determine the optimal 2×HBS solution to use for transfec-
tion. Transfections to produce AAV serotypes 1 and 5
were performed as described above with the exception
that 270 μg of the AAV1 and AAV5 serotypes plasmids
were transfected and the pHelper plasmid was not
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contained both capsid sequences and helper sequences re-
quired for making AAV viruses. AAV-misc is essentially
the same AAV shRNA genome plasmid that has been pre-
viously described [43] with the exception that the U6 based
shRNA expression cassette has been replaced with a H1
based shRNA expression cassette. AAV-misc based viruses
were produced and purified as described above.Viral titering
Purified AAV viruses were titered using a quantitative-
PCR based titering method. Five μl of purified viruses
were treated with 20 Units of DNase I (Roche) at 37°C
for 30 min and then further diluted in (10 mM Tris
pH 7.4, 10 μg/ml of yeast tRNA solution (Ambion)) to
make the final concentration of virus a 1:10,000 dilution
with respect to the undiluted virus. Five μl of the diluted
virus was used per a standard 20 μL Taqman PCR assay
(Applied Biosystems). One μl of a 20X Taqman custom
RFP Primer/Probe for AAV-RFP (RFP FP: AGCGCG
TGATGAACTTCGA,
RFP RP: GCCGATGAACTTCACCTTGTAGAT, RFP
Probe: 6FAM-ACCCAGGACTCCTCC) (as previously
described [53]) or GFP Primer/Probe (ID# Mr043296
76_mr, Invitrogen) for AAV-misc was used per reaction.
Samples were prepared and loaded onto a 96 well plate
in triplicate and quantitated using a CFX96 Real-time
PCR system (BioRad) using the standard cycling parame-
ters specified by Applied Biosystems. AAV-RFP and
AAV-misc viral genome copies were quantitated based
on a standard curve prepared by serially diluting the
pAAV-αCaMKII-RFP and pAAV-misc plasmids respect-
ively in (10 mM Tris pH 7.4, 10 μg/ml of yeast tRNA so-
lution) across eight, three fold serial dilutions ranging
from 1 × 103 to 3 × 106 copies of the viral genome plas-
mid per PCR reaction (as described above). Final viral ti-
ters were computed based on the standard curve and
reported as genome copies GC/ml.Viral titering of small scale viral crude lysate
Small scale transfections for AAV-RFP serotypes were
carried out in 12 well plates using standard Lipofecta-
mine transfection protocol (Life Technologies). Twenty
four hr before transfection, AAV-293 cells were seeded
in 12 well plates in AAV-293 growth media without anti-
biotics so that on the day of transfection the cells were
90-95% confluent. At the time of transfection, .53 μg of
pRC (serotype plasmid), .53 μg of pHelper and .53 μg
AAV2 genome plasmid were transfected into each well
following the manufacturer’s instructions (Invitrogen).
Seventy two hours post transfection the cells were har-
vested by centrifugation at 1500 g for 15 min and the
cell pellet was re-suspended in 36.5 μl of freezing buffer.The cells were then lysed by two freeze/thaw cycles in a
dry ice-ethanol bath and a 42°C water bath. Two and
one half units of benzonase (Novagen) were added to
the lysate and incubated for 30 min at 37°C. The lysate
was then clarified by centrifugation at 3700 g for 20 min
and the supernatant was used for PCR based viral titering.
The partially purified viruses were treated with 20 Units of
DNase I (Roche) at 37°C for 30 min and then diluted
1:1000 in (10 mM Tris pH 7.4, 10 μg/ml of yeast tRNA so-
lution) and were titered similarly as the large scale AAV
virus titering. The titers were reported as GC/ml. For this
experiment all samples were processed together in tripli-
cate to eliminate inter-experiment variability.Basolateral complex (BLA) viral infusions
Thirty-three gauge custom made infusion cannula (C315G,
Plastics One) were inserted into ~20 inch long polyethylene
tubing (I.D. 0.015 in, O.D. 0.043 in, wall thickness 0.0140
in) (A-M systems, Inc.). These tubes were backfilled with
sesame oil and then attached to 2 μl, 23-gauge (88500)
stainless steel Hamilton syringes (Hamilton Company).
Under a mixture of Ketamine (100 mg/kg) and Xylazine
(10.0 mg/kg) anesthesia, rats were stereotaxically implanted
bilaterally with a 33 gauge infusion cannula (described
above) targeting the BLA [AP -2.9, ML ±5.2, DV -8.6]. For
experiments depicted in Figures 4 and 5, 1.4 μl of the high-
est titer for each serotype (see Figure 2C), were bilaterally
infused for 15 minutes at a rate of 0.09 μl/min. For experi-
ments depicted in Figures 6 and 7, the viral titers for each
serotype were adjusted to 7.8E + 11 GC/ml using PBS-MK
and 1 μl was bilaterally infused for 15 min at the rate of
0.07 μl/min. Following infusions, the infusers were left in
for 10 additional min to allow for diffusion of the virus
away from the cannula after which they were withdrawn
and the incision was closed using 9 mm wound clips
(Mikron Precision, Inc.). The rats were allowed one week
for recovery and the wound clips were removed using a
wound clip remover (Mikron Precision, Inc.). Three weeks
post infusion, the rats were anesthetized with an overdose
of chloral hydrate (250 mg/kg) and then perfused with
phosphate-buffered saline (1× Phosphate buffer, 150 mM
NaCl) and 10% buffered Formalin (Fisher Scientific). The
brains were fixed in 10% formalin for 4-5 hours followed by
cryoprotection in 1×PBS pH7.4, 30% sucrose for 4-6 days.Imaging and quantification of viral transduction
Following cryoprotection, the brains were frozen and
40 μm coronal sections were obtained using a cryos-
tat which included the entire amygdala (Bregma -4.16
to -1.80). Every alternate section was placed on superfrost
slides (Fisherbrand) typically yielding ~40 sections per
amygdala. The remaining slices were stored in a solution
of PBS-MK with 0.1 mM sodium azide. The sections on
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inverted fluorescent microscope under RFP and bright
field filters and the images were acquired using an
Olympus DP72 Digital Camera and Cellsens software
(Olympus). Approximately 2500 images were taken and
analyzed for this project. For experiments depicted in
Figures 4 and 5, all fluorescence images were taken
under the same exposure conditions of 67 ms at 20X
magnification. For experiments depicted in Figures 6 and
7, all fluorescence images were taken under the same
exposure conditions of 1 s at 20X magnification. As a
result, images between these experiments cannot be
compared directly. All ~40 sections per amygdala were
quantified for viral transduction efficiency using Image-J
software to specifically measure spread of transduction
(Area (μm2)), mean red fluorescence intensity per trans-
duced region (optical density (OD)), and mean viral
transduction (Area*OD). For experiments depicted in
Figures 6 and 7, in addition to these three measure-
ments, the mean number of cells transduced was also
determined. Because targeted viral infusions within the
rodent brain even under the best circumstances will not
entirely localize viral transduction to the intended target
region, all 4 of these measures were taken for the total
viral transduction within each imaged coronal brain slice
(designated as Total within the figures), and the viral
transduction which occurred only within the borders of
the BLA (designated as BLA only within the figures).
The total viral transduction (Area*OD) per slice was
calculated by subtracting the background mean optical
density (OD) from the mean OD of the total area trans-
duced in each slice to create the OD of transduction per
slice. This value was multiplied by the total area trans-
duced within each slice, measured in μm2 to yield a
measure of total viral transduction per slice. The total
viral transduction per amygdala was recorded as the
sum of all measures of total viral transduction per slice
per amygdala and the total viral transduction per sero-
type was reported as the mean total viral transduction of
all amygdala infusions per serotype demonstrating trans-
duction. OD of total transduction was calculated for
every slice and averaged across all slices per amygdala to
yield total OD of transduction per amygdala and this
value was averaged among all infusions of a particular
serotype demonstrating transduction to yield mean total
OD of viral transduction per serotype. The total spread
of transduction per amygdala was recorded as the sum
of total area transduced in all slices per transduced
amygdala and this value was averaged among all infu-
sions of a particular serotype demonstrating transduct-
ion to yield mean total viral spread per serotype. For
BLA only viral transduction measurements, the OD and
viral spread were calculated as above with the exception
that the measurements were limited to the boundariesof the BLA in each slice and these measurements (BLA
only) are reported side by side with the Total measure-
ments within the figures. In experiments depicted in
Figures 4 and 5, approximately 40 slices per amygdala
were analyzed and a total of 4 amygdala per serotype
were analyzed, with the exception of AAV-DJ which 5
amygdala were analyzed. A total of 2-3 rats per serotype
were analyzed. For experiments depicted in Figures 6
and 7, in addition to the above mentioned measure-
ments we also counted the number of transduced cells.
To quantify the number of cells transduced, images were
imported into ImageJ and converted to grayscale 8 bit
images and the background subtraction function was ap-
plied. Next the threshold was set to 27 for the lower
level and 255(max) for the higher level. The watershed
function was applied and the cells within each image
were counted for the entire image and cells only within
the borders of the BLA were also counted (BLA only).
The cell counts were summed across all sections that ex-
hibited viral transduction per amygdala and cell counts
per amygdala per serotype were averaged to give mean cell
counts per serotype. For experiments depicted in Figures 6
and 7, approximately 40 slices per amygdala were analyzed
and a total of 7-10 amygdala per serotype across 4-8 rats
per serotype were analyzed (AAV2/1, AAV2/7, n = 7;
AAV2/5, AAV2/8, AAV2/9, AAV2/rh10, n = 8; AAV2/DJ,
n = 9; AAV2/DJ8, n = 10; n refers to number of amygdala
per serotype analyzed). Non-parametric statistics were
applied to evaluate statistical differences in transduction
efficiency among serotypes examined using the Kruskal-
Wallis test with a Dunn-Bonferroni post hoc test. Differ-
ences were considered significant if, p < 0.05 (uncorrected
for multiple comparisons); however in many cases, signifi-
cance was reached when correcting for multiple compari-
sons. Tables containing the p-values from statistical
comparisons among the serotypes for mean viral transduc-
tion (total and BLA only), mean viral spread (total and
BLA only) and mean number of transduced cells (total and
BLA only) are provided in (Additional file 1: Table S1).
Sequence analysis
To generate the phylogram comparing the VP1 capsid
proteins for the AAV serotypes used in this study, the VP1
amino acid sequences for all of the serotypes were first
aligned using ClustalOmega (EMBL-EBI) [54] using the
default parameters. The resulting phylogenetic tree output
file was then imported into Phylodendron software (ver-
sion 0.8d, beta January 1999; http://iubio.bio.indiana.edu/
treeapp/) to generate the phenogram. To produce the se-
quence similarity/divergence table for the AAV serotype
VP1 capsid proteins, the VP1 amino acid sequences for all
serotypes were imported into MegAlign Software version
3.05a (DNASTAR, Inc.) and aligned using the Clustal
method and the pair-wise sequence distances were
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due weight table.
Immunohistochemistry
For immunohistochemistry (IHC), 1 μl of virus was bilat-
erally infused into the BLA at a titer of 7.8E + 11 GC/ml as
described above. Twenty one days post infusion, the rats
were anesthetized with an overdose of chloral hydrate
(250 mg/kg) and then perfused with 4% Paraformaldehyde
in 1 × PBS (pH = 7.4). Following brain extraction, the
brains were fixed in 4% Paraformaldehyde in 1×PBS (pH =
7.4) for 4-5 hr, followed by cryoprotection in 1×PBS pH7.4,
30% sucrose for 4-6 days. Following cryoprotection, the
brains were frozen and 40 μm coronal sections were ob-
tained using a cryostat as described above. For NeuN IHC,
brain slices were rinsed in 1×PBS for 10 min followed by
incubation for 30 min with blocking buffer (1× PBS, 3%
normal donkey serum, 0.3% Triton X-100). Next the slices
were incubated overnight at 4°C with NeuN Antibody
(1:500; MAB377 Millipore, Billerica, MA), diluted in block-
ing buffer. For the αCaMKII IHC, brain slices were rinsed
in 1×PBS for 10 min followed by incubation for 60 min
with blocking buffer (1X PBS, 5% normal donkey serum,
0.3% Triton X-100). Next the slices were incubated over-
night at 4°C with αCaMKII Antibody (1:300; 05-532,
Millipore), diluted in antibody dilution buffer (1XPBS, 1%
BSA, 0.3% Triton X-100). For secondary antibody staining
1:500 dilution of fluorescein isothiocyanate (FITC) conju-
gated anti-Mouse IgG (AP192F; Millipore) was used and
the slices were incubated for 2 hr at room temperature.
The slides were coverslipped with Vectashield HardSet
Mounting Medium (Vector Laboratories). IHC images
were captured at 100× magnification using an Olympus
BX51 upright fluorescence microscope with an Olympus
DP71 Digital Camera and DP manager software. The num-
ber of AAV transduced (RFP) cells within the BLA that
were also NeuN positive or αCaMKII positive was deter-
mined by quantifying the number of RFP cells that also co-
localized with the NeuN or αCaMKII FITC signal within
an area of 135173.56 μm2 from within the BLA of each
slice examined. The area within each slice quantified typic-
ally contained ~ 65 RFP positive cells and a total of three
slices were counted per serotype. Cells were manually
quantified using Adobe Photoshop CS5 software and the
colocation results were reported as a percentage of total
RFP cells counted. Variability in co-localization results be-
tween slices was reported as standard error of the mean.Additional file
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